Jane Street
ENTA icon

Jane Street’s Enanta Pharmaceuticals ENTA Stock Holding History

Jane Street’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,165
Closed -$229K – 11428
2025
Q3 		$229K Sell
19,165
-6,334
-25% -$50.6K ﹤0.01% 9410
2025
Q2 		$193K Buy
25,499
+913
+4% +$5.49K ﹤0.01% 8576
2025
Q1 		$136K Sell
24,586
-6,486
-21% -$40.1K ﹤0.01% 8668
2024
Q4 		$179K Buy
31,072
+7,896
+34% +$75.7K ﹤0.01% 8486
2024
Q3 		$240K Sell
23,176
-5,507
-19% -$72K ﹤0.01% 8384
2024
Q2 		$372K Buy
28,683
+7,765
+37% +$105K ﹤0.01% 7472
2024
Q1 		$365K Sell
20,918
-53,522
-72% -$708K ﹤0.01% 7231
2023
Q4 		$700K Sell
74,440
-69,639
-48% -$649K ﹤0.01% 6191
2023
Q3 		$1.61M Buy
144,079
+134,360
+1,382% +$2.16M ﹤0.01% 4409
2023
Q2 		$208K Sell
9,719
-10,467
-52% -$309K ﹤0.01% 7642
2023
Q1 		$816K Buy
+20,186
New +$964K ﹤0.01% 5399
2022
Q1 		– Sell
-3,157
Closed -$236K – 10452
2021
Q4 		$236K Buy
+3,157
New +$248K ﹤0.01% 8571
2021
Q3 		– Sell
-9,060
Closed -$448K – 10106
2021
Q2 		$399K Buy
+9,060
New +$444K ﹤0.01% 7668
2021
Q1 		– Sell
-4,753
Closed -$200K – 9203
2020
Q4 		$200K Sell
4,753
-1,014
-18% -$44.6K ﹤0.01% 6954
2020
Q3 		$264K Buy
5,767
+1,632
+39% +$79.1K ﹤0.01% 6062
2020
Q2 		$208K Buy
+4,135
New +$214K ﹤0.01% 6327
2020
Q1 		– Sell
-4,826
Closed -$298K – 5443
2019
Q4 		$298K Sell
4,826
-1,054
-18% -$65.3K ﹤0.01% 4278
2019
Q3 		$353K Buy
5,880
+3,418
+139% +$254K ﹤0.01% 3973
2019
Q2 		$208K Buy
+2,462
New +$221K ﹤0.01% 4653
2019
Q1 		– Sell
-5,364
Closed -$380K – 5147
2018
Q4 		$380K Buy
+5,364
New +$411K ﹤0.01% 3784
2014
Q4 		– Sell
-5,981
Closed -$237K – 2606
2014
Q3 		$237K Sell
5,981
-4,870
-45% -$194K ﹤0.01% 2072
2014
Q2 		$467K Buy
+10,851
New +$414K 0.01% 1472

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street's ENTA Position: Q4 2025 in Review

Jane Street sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 19,165 shares — an estimated $229K sold.

Jane Street first reported a position in ENTA in Q2 2014 and held it in 22 quarters. The position peaked at $1.61M in Q3 2023. 132 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Jane Street reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Jane Street sold 19,165 Enanta Pharmaceuticals shares in Q4 2025, an estimated $229K.
  • Jane Street first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 22 quarters.
  • Jane Street's Enanta Pharmaceuticals position peaked at $1.61M in Q3 2023.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Jane Street's 13F filing for Q4 2025, filed 12 Feb 2026.